Evonik Balances Lab Bench and Boardroom as BASF Waits on the Books

Evonik has spent October working on two fronts that rarely meet: the laboratory and the negotiating table. The specialty chemicals group launched a polyurethane foam recycling initiative in Japan, picked up a pharma award for its automated research platform, rolled out new dental plastics and a ruminant feed additive — all while a potential suitor circles with a conditional offer that remains unconfirmed.

The distinction matters for shareholders. Operational announcements document individual business steps; the takeover question is still hedged with preconditions. The next scheduled financial event is the quarterly statement on 3 November 2026.

Recycling and research wins, without a proven earnings contribution

On 13 October, Evonik kicked off a chemical recycling initiative for polyurethane foam in Japan alongside Toyotsu Chemiplas and Sanyo Chemical Industries. The waste is to be converted into recycled polyols and amines for new polyurethane products, feeding discarded material back into manufacturing. What is confirmed is the project's launch — not an economic result already booked. A start date is not the same as a realized contribution to earnings.

Research brought its own headline. Evonik received the CPHI Pharma Award 2026 in the "Digital Transformation" category for its "Self Driving Labs," with the ceremony held on 6 October at the CPHI trade fair in Milan.

Product launches round out the operating picture

Yesterday the company presented two stiffer VESTAKEEP PEEK grades for long-term dental prosthetics, designed for both fixed and removable restorations and for standard CAD/CAM workflows. Monday brought Lypron, a rumen-protected lysine solution for ruminants that extends Evonik's amino acid balancing concept; production is handled exclusively by the French coating specialist Sipena.

These announcements span quite different applications, and their weight lies first in the products introduced and the manufacturing arrangement agreed. A product launch, however, does not equal proven revenue or profit growth. Investors should resist reading operational progress as an immediate financial acceleration.

A higher BASF bid stays a possibility, not an offer

Last week dpa-AFX reported, citing circles, that BASF was prepared to discuss a higher offer — conditional on gaining insight into Evonik's books. The first bid of EUR 22.15 per share had been rejected by Evonik as too low. Any increase is therefore neither a confirmed new offer nor a secured transaction, and it forms a different valuation factor from the projects actually underway.

The reported willingness to improve terms is tied to that condition. BASF first wants to examine Evonik's books, and from that readiness alone neither a new offer price nor a successful path for the takeover plans can be derived. The potential sweetener is no standalone purchase promise; what would count is whether the reported review leads to concrete negotiations and ultimately a binding offer.

Evonik shares trade at EUR 21.02. That price is no evidence of what BASF might actually bid after a possible look at the books — the market valuation and the terms of any takeover must be viewed separately.

Financing dispute and political pressure add noise

The debate gained extra edge on Friday from comments by IG BCE chief Michael Vassiliadis, who spoke of "problematic financing issues" at Evonik. According to Handelsblatt, Evonik firmly rejected the statement and pointed to recently improved credit ratings. A union warning and the company's explicit rebuttal thus stand opposite each other; Vassiliadis's remark must not be treated as an established financing problem, and Evonik's ratings reference does not answer the question of what conditions a possible BASF offer would carry.

On Saturday, media reported growing concerns about jobs in connection with a possible takeover, pushing the debate beyond the offer price. Economy Minister Mona Neubaur had already spoken out against a BASF takeover on 14 October. CDU parliamentarian Björn Franken stated in the NRW state parliament that no binding takeover offer had been submitted to date.

For Evonik investors the central boundary stays clear: political positions, employment worries and reported price considerations do not substitute for a confirmed transaction. The latest report opens a perspective on further negotiations but expressly does not confirm that they have resumed. The 3 November quarterly report, meanwhile, turns attention to the company's financial development — separate from the question of whether BASF sharpens its plans with another offer.